Analyst Price Target is $132.00
▲ +9.87% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Twist Bioscience in the last 3 months. The average price target is $132.00, with a high forecast of $200.00 and a low forecast of $100.00. The average price target represents a 9.87% upside from the last price of $120.14.
Current Consensus is
The current consensus among 6 investment analysts is to hold stock in Twist Bioscience. This rating has held steady since January 2021, when it changed from a Buy consensus rating.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.